Literature DB >> 11570583

Monocyte and monocyte-derived macrophage secretion of MCP-1 in co-culture with autologous malignant and benign control fragment spheroids.

J H Heimdal1, C Olsnes, J Olofsson, H J Aarstad.   

Abstract

This study was performed in order to determine how monocytes and macrophages in co-culture with autologous head and neck squamous cell carcinoma (HNSCC) tumor tissue regulate the secretion of monocyte chemotactic protein-1 (MCP-1). The levels of MCP-1 were measured when autologous monocytes or monocyte-derived macrophages (MDMs) were co-cultured in vitro with autologous fragment (F)-spheroids established from HNSCC tumors or benign mucosa serving as control. MCP-1 secretion from co-culture stimulated monocytes and MDMs was increased compared to spontaneous MCP-1 secretion. With prolonged co-culture, MDMs showed a steady-state MCP-1 secretion above background levels for up to 96 h, even with change of co-culture media every 24 h. Addition of an anti-MCP-1 antibody to the medium decreased co-culture-induced monocyte IL-6 secretion. Addition of lipopolysaccharide (LPS) (1 [microg/ml) reduced MCP-1 secretion compared to spontaneous secretion in monocyte cultures. F-spheroids also secrete MCP-1, but at insignificant levels compared to the MCP-1 secretion from monocytes and MDMs. MCP-1 secretion from monocytes/MDMs is regulated differently when co-culture stimulation is compared to LPS-stimulation. Monocytes and MDMs expressed MCP-1 mRNA at a high level in all tested conditions: stimulated in co-culture, not stimulated or stimulated with LPS, indicating post-transcriptional regulation of MCP-1 secretion. The secretion of MCP-1 from tumor-derived F-spheroids, and the maintenance of co-culture MCP-1 secretion from MDMs in vitro, suggests that tumor-associated macrophages are a source of MCP-1 in HNSCC tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570583     DOI: 10.1007/s002620100204

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors.

Authors:  Carla Olsnes; John-Helge Heimdal; Kenneth W Kross; Jan Olofsson; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

2.  Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures.

Authors:  Lorenz Kadletz; Gregor Heiduschka; Julian Domayer; Rainer Schmid; Elisabeth Enzenhofer; Dietmar Thurnher
Journal:  Oncol Lett       Date:  2015-07-14       Impact factor: 2.967

3.  Rs7853346 Polymorphism in lncRNA-PTENP1 and rs1799864 Polymorphism in CCR2 are Associated with Radiotherapy-Induced Cognitive Impairment in Subjects with Glioma Via Regulating PTENP1/miR-19b/CCR2 Signaling Pathway.

Authors:  Sen Yang; Zhan-Zhao Fu; Yan-Qiu Zhang; Bao-Hong Fu; Li-Xin Dong
Journal:  Biochem Genet       Date:  2021-11-19       Impact factor: 2.220

4.  CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.

Authors:  Alan L Chang; Jason Miska; Derek A Wainwright; Mahua Dey; Claudia V Rivetta; Dou Yu; Deepak Kanojia; Katarzyna C Pituch; Jian Qiao; Peter Pytel; Yu Han; Meijing Wu; Lingjiao Zhang; Craig M Horbinski; Atique U Ahmed; Maciej S Lesniak
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

5.  Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma.

Authors:  Yujuan Sun; Nan Liu; Xiaobing Guan; Hongru Wu; Zheng Sun; Hui Zeng
Journal:  Mediators Inflamm       Date:  2016-12-08       Impact factor: 4.711

Review 6.  Ex Vivo Culture Models to Indicate Therapy Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Imke Demers; Johan Donkers; Bernd Kremer; Ernst Jan Speel
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.